Filing Analysis
Lipocine Inc. filed an 8-K/A to amend a previous filing, reporting the appointment of Michael Grissinger to the Company's Compensation Committee. The amendment specifies the additional compensation associated with this committee role.
๐ Key Facts
- Michael Grissinger was appointed to the Compensation Committee of the Board on August 18, 2026.
- Mr. Grissinger is eligible to receive an additional $7,500 per year for his service on the Compensation Committee.
- The filing is an amendment (8-K/A) to a previous report regarding his appointment to the Board.
Lipocine Inc. filed an 8-K to announce the release of its financial and operational results for the quarter ended June 30, 2026.
๐ Key Facts
- Report date: August 4, 2026
- Reporting period: Quarter ended June 30, 2026
- The filing includes a press release (Exhibit 99.1) detailing financial and operational results.
- Signed by Mahesh V. Patel, President and CEO.
Lipocine Inc. announced the expansion of its Board of Directors through the appointment of Michael Grissinger as an independent director, effective August 3, 2026.
๐ Key Facts
- Michael Grissinger appointed to the Board of Directors on August 3, 2026.
- The Board has expanded from four to five members.
- Mr. Grissinger is designated as an independent director under Nasdaq listing standards.
- Compensation includes an initial stock option grant for 2,000 shares and an annual retainer of $55,000.
Lipocine Inc. hosted a virtual Key Opinion Leader (KOL) event on June 12, 2026, to discuss the clinical profile of its candidate LPCN 1154 and the unmet medical needs regarding postpartum depression.
๐ Key Facts
- Event date: June 12, 2026
- Focus of presentation: Clinical profile of LPCN 1154
- Therapeutic area: Postpartum depression
- The presentation was furnished as Exhibit 99.1
Lipocine Inc. reported the results of its annual general meeting of shareholders held on June 3, 2026. Key outcomes included the election of four directors, the ratification of Tanner LLC as the independent auditor, and the approval of amendments to the 2014 Stock and Incentive Plan.
๐ Key Facts
- Shareholders approved the Sixth Amended and Restated 2014 Stock and Incentive Plan on June 3, 2026.
- The 2014 Plan amendment increased individual award limits from 25,000 to 100,000 shares.
- The total authorized common stock awards under the 2014 Plan increased by 400,000 shares, bringing the total to 1,000,000 shares.
- Four directors were elected for one-year terms: Dr. Mahesh V. Patel, John W. Higuchi, Dr. Jill M. Jene, and Dr. Richard Dana Ono.
- Tanner LLC was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2026.
Lipocine Inc. announced it will host a virtual Key Opinion Leader (KOL) event on June 12, 2026, to discuss the clinical profile of its candidate LPCN 1154 and unmet needs in postpartum depression.
๐ Key Facts
- Event date: June 12, 2026, at 11:00 AM Eastern Time
- Focus of event: Clinical profile of LPCN 1154 and postpartum depression
- Format: Virtual KOL event
Lipocine Inc. (LPCN) filed an 8-K to report the presentation of Phase 3 clinical data for LPCN 1154 (oral brexanolone) for the treatment of postpartum depression (PPD) at the American Society of Clinical Psychopharmacology (ASCP) Annual Meeting.
๐ Key Facts
- Presentation and poster presented on May 26, 2026, at the ASCP Annual Meeting in Miami Beach, FL.
- The data pertains to a Phase 3 placebo-controlled trial for LPCN 1154 (oral brexanolone) for the treatment of postpartum depression (PPD).
- The presentation and poster are included as Exhibit 99.1 and 99.2.
Lipocine Inc. announced that Phase 3 clinical data for its drug candidate LPCN 1154 has been accepted for an oral presentation at the 2026 American Society of Clinical Psychopharmacology (ASCP) Annual Meeting. The presentation will take place during the conference held from May 26-29, 2026, in Miami, Florida.
๐ Key Facts
- Lipocine's LPCN 1154 Phase 3 data was accepted for oral presentation.
- The presentation will take place at the 2026 ASCP Annual Meeting in Miami, Florida.
- The conference is scheduled for May 26-29, 2026.
- The announcement was disclosed via a press release on May 19, 2026.
Lipocine Inc. announced that it will be presenting at A.G.P.โs Annual Virtual Healthcare Company Showcase on May 20, 2026. The company issued a press release on May 18, 2026, to disclose the upcoming event.
๐ Key Facts
- Lipocine to present at A.G.P.โs Annual Virtual Healthcare Company Showcase.
- The presentation is scheduled for Wednesday, May 20, 2026.
- The announcement was filed under Item 8.01 (Other Events) and includes the press release as Exhibit 99.1.
Lipocine Inc. filed an updated corporate presentation on May 7, 2026, intended for use in meetings with investors, analysts, and other parties. The presentation is included as Exhibit 99.1 in the filing.
๐ Key Facts
- Filing date: May 7, 2026
- The company updated its corporate presentation for investor and analyst communications
- The presentation is filed under Item 8.01 (Other Events)
- Exhibit 99.1 contains the full corporate presentation
Lipocine Inc. announced its financial and operational results for the first quarter ended March 31, 2026. The disclosure was made via a press release furnished as Exhibit 99.1.
๐ Key Facts
- The filing reports financial and operational results for the quarter ended March 31, 2026.
- The report was filed under Item 2.02 (Results of Operations and Financial Condition).
- The report was signed by Mahesh V. Patel, President and Chief Executive Officer, on May 7, 2026.
Lipocine Inc. announced the immediate resignation of its Board Chairman and Lead Independent Director, Spyros Papapetropoulos, effective April 16, 2026. The departure is notably attributed to internal conflict regarding the company's strategic direction.
๐ฉ Red Flags
- Resignation of the Chairman of the Board due to 'differing views on the Companyโs strategic direction' indicates significant internal governance conflict.
- Immediate effectiveness of the resignation suggests an abrupt departure.
๐ Key Facts
- Spyros Papapetropoulos resigned as Chairman, Lead Independent Director, and compensation committee member effective April 16, 2026.
- The resignation was explicitly linked to 'differing views on the Companyโs strategic direction' and competing professional commitments.
- R. Dana Ono was appointed as the new Chairman of the Board and Lead Independent Director on April 20, 2026.
- Dr. Papapetropoulos had served on the Board since 2022.
Lipocine Inc. filed an 8-K to announce an update to its corporate presentation used for meetings with investors, analysts, and other stakeholders. The updated presentation was included as Exhibit 99.1 in the filing.
๐ Key Facts
- Filing date: April 2, 2026
- The company updated its corporate presentation for use with 'investors, analysts and others'
- The presentation is filed as Exhibit 99.1
- The report was filed under Item 8.01 (Other Events)
Lipocine Inc. announced topline safety and efficacy results for its drug candidate LPCN 1154, aimed at treating postpartum depression. The results were disclosed via a press release on April 2, 2026, and filed under Item 8.01 of the Form 8-K.
๐ Key Facts
- The company reported topline safety and efficacy results for LPCN 1154 on April 2, 2026.
- LPCN 1154 is being developed for the treatment of patients with postpartum depression (PPD).
- The results were incorporated by reference from Exhibit 99.1, a press release issued by the company.
- The filing was made under Item 8.01 (Other Events) rather than Item 7.01, indicating the company considers the results material.
Lipocine Inc. announced its financial and operational results for the fiscal year ended December 31, 2025, via a press release furnished on March 10, 2026.
๐ Key Facts
- The company reported financial results for the full year ended December 31, 2025
- The report was filed under Item 2.02 (Results of Operations and Financial Condition)
- A press release detailing the results was furnished as Exhibit 99.1
- The filing was signed by President and CEO Mahesh V. Patel on March 10, 2026
Lipocine Inc. filed a prospectus supplement on February 26, 2026, to sell up to $50 million of its common stock through an at-the-market (ATM) offering. The sales will be conducted through A.G.P./Alliance Global Partners under a Sales Agreement originally established in April 2024.
๐ฉ Red Flags
- Potential for significant shareholder dilution given the $50 million offering size relative to the micro-cap status of the company.
- Frequent reliance on ATM offerings can indicate a high cash burn rate or difficulty securing traditional debt financing.
๐ Key Facts
- Prospectus supplement filed on February 26, 2026, for an aggregate of $50,000,000 in common stock.
- The offering utilizes an existing Sales Agreement with A.G.P./Alliance Global Partners dated April 26, 2024.
- Legal validity of the shares was confirmed by Dorsey & Whitney LLP in Exhibit 5.1.
- The filing was made under Item 8.01 (Other Events) rather than Item 1.01.
Lipocine Inc. has filed an 8-K to announce the update of its corporate presentation used for investor and analyst meetings.
๐ Key Facts
- The company updated its corporate presentation (Exhibit 99.1).
- The filing date is February 18, 2026.
- The report was signed by Mahesh V. Patel, President and CEO.
Lipocine Inc. announced the completion of the Last Patient Last Visit (LPLV) in its pivotal Phase 3 clinical trial for postpartum depression (PPD). The company also provided preliminary, unaudited cash position estimates as of January 31, 2026.
๐ฉ Red Flags
- The reported cash position ($19M) is preliminary and unaudited; actual figures may vary upon completion of audit/closing.
๐ Key Facts
- Completed Last Patient Last Visit (LPLV) for the pivotal Phase 3 clinical trial of LPCN 1154 for Postpartum Depression (PPD).
- Reported approximately $19 million in cash and cash equivalents as of January 31, 2026.
- Cash position estimate is preliminary, unaudited, and subject to final financial closing procedures.
Lipocine Inc. announced the completion of enrollment and dosing for its Phase 3 clinical trial of LPCN 1154, intended to treat postpartum depression (PPD). This marks a significant milestone in the company's clinical development pipeline.
๐ Key Facts
- Completed enrollment and dosing in Phase 3 Trial of LPCN 1154.
- The trial targets Postpartum Depression (PPD).
- Announcement made via press release on January 20, 2026.
Lipocine Inc. has filed an 8-K to announce the update of its corporate presentation used for investor and analyst communications.
๐ Key Facts
- The company updated its corporate presentation (Exhibit 99.1).
- Filing date: January 12, 2026.
- The update is intended for use in meetings with investors, analysts, and other stakeholders.
Lipocine Inc. issued a press release regarding positive progress following the second interim safety review of its Phase 3 clinical trial for LPCN 1154, targeting postpartum depression.
๐ Key Facts
- The company reported encouraging progress in the Phase 3 Trial of LPCN 1154.
- The update follows a second interim safety review.
- The indication being studied is postpartum depression.
Lipocine Inc. announced a clinical milestone regarding its PPD Phase 3 Study (LPCN 1154), reporting that the study has reached 80% enrollment. This is an operational update related to clinical trial progress.
๐ Key Facts
- PPD Phase 3 Study (LPCN 1154) has achieved 80% patient enrollment.
- The announcement was made via press release on December 16, 2025.
- Enrollment progress is a key milestone for the clinical development timeline of LPCN 1154.
Lipocine Inc. announced that Jeffrey Fink will resign from the Board of Directors effective January 1, 2026, citing personal reasons. The company stated there were no disagreements with the Company regarding his departure.
๐ Key Facts
- Jeffrey Fink to resign from the Board of Directors effective January 1, 2026.
- Resignation is for personal reasons.
- The resignation was not due to any disagreement with the Company.
- The Board intends to conduct a search for a replacement director.
Lipocine Inc. announced the presentation of scientific posters regarding its drug candidates, LPCN 2101, at the American Epilepsy Society (AES) Annual Meeting held in December 2025.
๐ Key Facts
- The company presented two posters at the AES Annual Meeting in Atlanta, GA (Dec 5-9, 2025).
- Poster 1: 'Clinical Pharmacokinetics and Tolerability of a Novel Oral GABA A Receptor Positive Allosteric Modulating Candidate for Epilepsy'.
- Poster 2: 'Oral Toxicokinetics of a Bioidentical GABA A Receptor Modulating Neuroactive Steroid Anti-Seizure Medication Candidate for Women with Epilepsy'.
Lipocine Inc. has filed an 8-K to announce the update of its corporate presentation used for investor and analyst meetings.
๐ Key Facts
- The company updated its corporate presentation (Exhibit 99.1).
- The filing was made on November 18, 2025.
- The purpose is to provide current information to investors, analysts, and other stakeholders.
Lipocine Inc. issued a press release regarding promising interim safety data for its Phase 3 clinical trial of LPCN 1154, targeting postpartum depression (PPD). The filing is an 'Other Event' intended to communicate positive clinical progress.
๐ Key Facts
- Interim safety profile for LPCN 1154 in Phase 3 clinical trials was reported as promising.
- The trial target indication is Postpartum Depression (PPD).
- The announcement was made via a press release furnished as Exhibit 99.1.
Lipocine Inc. filed an 8-K to announce the release of its financial and operational results for the quarter ended September 30, 2025.
๐ Key Facts
- Report date: November 6, 2025
- Reporting period: Quarter ended September 30, 2025
- The filing is a standard announcement of quarterly earnings results via press release (Exhibit 99.1).
Lipocine Inc. issued an 8-K to announce the presentation of clinical data for its LPCN 2401 candidate at the ObesityWeekยฎ conference in Atlanta, GA.
๐ Key Facts
- The company presented clinical data regarding LPCN 2401 on November 4, 2025.
- The event is ObesityWeekยฎ, held from November 4th through November 7th in Atlanta, GA.
- A press release was issued as Exhibit 99.1 to accompany this filing.
Lipocine Inc. issued an 8-K to provide a progress update regarding the ongoing Phase 3 clinical trial of its product LPCN 1154 for the treatment of Postpartum Depression (PPD). The filing serves primarily as a vehicle to furnish a press release containing clinical development updates.
๐ Key Facts
- The company provided an update on the Phase 3 clinical trial for LPCN 1154.
- The target indication for the clinical trial is Postpartum Depression (PPD).
- The filing was signed by Mahesh V. Patel, President and CEO, on September 30, 2025.
Lipocine Inc. has updated its corporate presentation to reflect a strategic pause in the clinical development of LPCN 2401. While IND clearance was received for a Proof of Concept (POC) study as an adjunct to GLP-1 therapy, the company is delaying the study to seek regulatory clarity on specific endpoints.
๐ฉ Red Flags
- Delay in clinical trial progression for a key asset (LPCN 2401) due to regulatory uncertainty regarding study endpoints.
๐ Key Facts
- Company received IND clearance for POC study of LPCN 2401 (adjunct to GLP-1 therapy).
- The company is pausing the POC study to seek regulatory clarity regarding development paths and study endpoints (e.g., functional loss).
- Updated corporate presentation filed as Exhibit 99.1.
Lipocine Inc. announced its participation in the H.C. Wainwright 27th Annual Global Investor Conference scheduled for September 8-10, 2025.
๐ Key Facts
- Company will present and meet with investors at the H.C. Wainwright 27th Annual Global Investor Conference.
- Conference dates: September 8-10, 2025.
- Location: New York City, New York.
Lipocine Inc. announced its participation in the H.C. Wainwright 27th Annual Global Investor Conference scheduled for September 8-10, 2025. The company provided a presentation to be used during investor meetings.
๐ Key Facts
- Company is presenting at the H.C. Wainwright 27th Annual Global Investor Conference in New York City.
- Conference dates: September 8-10, 2025.
- A presentation was furnished as Exhibit 99.1.
Lipocine Inc. announced that abstracts for its LPCN 2101 program have been accepted for presentation at the 2025 American Epilepsy Society (AES) annual meeting scheduled for December 2025.
๐ Key Facts
- LPCN 2101 abstracts were accepted for presentation at the AES annual meeting.
- The AES annual meeting is scheduled to take place from December 5-9, 2025, in Atlanta, Georgia.
- The announcement was made via a press release on August 26, 2025.
Lipocine Inc. filed an 8-K to announce the release of its financial and operational results for the quarter ended June 30, 2025.
๐ Key Facts
- The filing is a standard announcement of quarterly earnings (Item 2.02).
- Reporting period: Quarter ended June 30, 2025.
- Filing date: August 5, 2025.
- The company's press release containing the actual financial data is attached as Exhibit 99.1.
Lipocine Inc. hosted a virtual Key Opinion Leader (KOL) event on July 9, 2025, to discuss the development of LPCN 1154 (BRLIZIOโข) for the treatment of postpartum depression.
๐ Key Facts
- Event date: July 9, 2025
- Subject matter: Virtual KOL event regarding LPCN 1154 (BRLIZIOโข)
- Indication: Treatment for postpartum depression
- Presentation available on corporate website via Exhibit 99.1
Lipocine Inc. has filed an 8-K to announce the update of its corporate presentation used for investor and analyst meetings.
๐ Key Facts
- The company updated its corporate presentation (Exhibit 99.1) as of July 2, 2025.
- The filing is intended to provide updated information to investors, analysts, and other stakeholders.
Lipocine Inc. announced the successful dosing of the first patient in its Phase 3 clinical trial for LPCN 1154, targeting postpartum depression. This represents a significant milestone in the company's clinical development pipeline.
๐ Key Facts
- First patient has been dosed in the Phase 3 clinical trial for LPCN 1154.
- The target indication for the trial is postpartum depression.
- Announcement made via press release on June 26, 2025.
Lipocine Inc. announced a virtual R&D investor event scheduled for July 9, 2025. The presentation will focus on the development of LPCN (BRLIZIOโข) as a potential treatment for postpartum depression.
๐ Key Facts
- Virtual R&D investor event scheduled for Wednesday, July 9, 2025, at 11:00 am ET.
- The focus of the event is LPCN (BRLIZIOโข) regarding its application as a treatment for postpartum depression.
- Press release issued on June 23, 2025.
Lipocine Inc. announced that its licensing partner, Verity Pharma, has filed a New Drug Submission for the product TLANDOยฎ in Canada.
๐ Key Facts
- Licensing partner Verity Pharma filed a New Drug Submission for TLANDOยฎ in Canada.
- The announcement was made via press release on June 9, 2025.
- The filing is categorized under Item 8.01 (Other Events).
Lipocine Inc. held its annual general meeting on June 4, 2025, where shareholders approved a significant reduction in authorized shares from 200 million to 75 million. The meeting also included the election of six directors and ratification of the company's independent auditor.
๐ฉ Red Flags
- Significant reduction in authorized shares (62.5% decrease) can sometimes be a precursor to or part of a reverse stock split strategy to maintain exchange listing requirements, though not explicitly labeled as such here.
- High number of 'Broker Non-Votes' across director elections suggests significant institutional or proxy voting friction.
๐ Key Facts
- Shareholders approved an amendment to reduce authorized common stock from 200,000,000 to 75,000,000 shares.
- Six directors were elected for one-year terms: Dr. Mahesh V. Patel, Jeffrey A. Fink, John W. Higuchi, Dr. Jill M. Jene, Dr. Richard Dana Ono, and Dr. Spyros Papapetropoulos.
- Tanner LLC was ratified as the independent registered public accounting firm for fiscal year ending Dec 31, 2025.
- A non-binding advisory vote on executive compensation was approved by shareholders.
Lipocine Inc. announced that its development candidate LPCN 1148 for the treatment of men with cirrhosis has been selected for feature in the 'Hepatology Highlights' section of the June 2025 edition of Hepatology journal.
๐ Key Facts
- Development candidate LPCN 1148 is being featured in 'Hepatology Highlights'.
- The feature will appear in the June 2025 edition of the journal 'Hepatology'.
- LPCN 1148 is targeting men with cirrhosis.
Lipocine Inc. announced its intention to present at A.G.P.โs Annual Healthcare Company Showcase, scheduled for May 21, 2025.
๐ Key Facts
- Company will participate in A.G.P.โs Annual Healthcare Company Showcase.
- The event is scheduled to take place virtually on Wednesday, May 21, 2025.
- The announcement was made via a press release filed as Exhibit 99.1.
Lipocine Inc. has filed an 8-K to announce the update of its corporate presentation used for investor and analyst meetings.
๐ Key Facts
- The company updated its corporate presentation (Exhibit 99.1).
- The filing was signed by Mahesh V. Patel, President and CEO.
- The report date is May 12, 2025.
Lipocine Inc. filed an 8-K to announce the release of its financial and operational results for the fiscal quarter ended March 31, 2025.
๐ Key Facts
- The filing is a standard announcement of quarterly earnings (Q1 2025).
- Results cover the period ending March 31, 2025.
- The company issued a press release as Exhibit 99.1 to accompany this report.
Lipocine Inc. has entered into a License and Supply Agreement with Achรฉ Laboratรณrios Farmacรชuticos S.A. to commercialize its TLANDOยฎ product in Brazil for various testosterone replacement therapy indications.
๐ Key Facts
- Agreement partner: Achรฉ Laboratรณrios Farmacรชuticos S.A.
- Product: TLANDOยฎ (testosterone replacement therapy).
- Territory: Brazil.
- Indications included: Testosterone deficiency/absence in males, Klinefelter syndrome, and pediatric indications.
- Filing date: May 6, 2025.
Lipocine Inc. has filed an 8-K to announce the update of its corporate presentation used for investor and analyst meetings.
๐ Key Facts
- The company updated its corporate presentation (Exhibit 99.1).
- The filing was made on April 3, 2025.
- The purpose is to provide current information to investors, analysts, and other stakeholders.
Lipocine Inc. announced the initiation of an outpatient Phase 3 clinical trial for its candidate LPCN 1154, targeting postpartum depression. This represents a significant milestone in the company's clinical development pipeline.
๐ Key Facts
- Initiation of an outpatient Phase 3 clinical trial for LPCN 1154.
- The trial focuses on treating postpartum depression.
- Announcement made via press release on March 26, 2025.
Lipocine Inc. filed an 8-K to announce the release of its financial and operational results for the fiscal year ended December 31, 2024.
๐ Key Facts
- The filing is a formal announcement of annual financial and operational results.
- Reporting period: Year ended December 31, 2024.
- Filing date: March 13, 2025.
- The full press release containing specific metrics is incorporated by reference as Exhibit 99.1.
Lipocine Inc. announced that the FDA has informed sponsors of approved testosterone products regarding class-wide labeling changes. This regulatory development may impact the company's product positioning or marketing requirements for its testosterone-related assets.
๐ฉ Red Flags
- Regulatory uncertainty: Class-wide labeling changes can sometimes involve new warnings or restrictions that may impact market uptake or physician prescribing habits.
๐ Key Facts
- Date of report: March 12, 2025
- The FDA has informed sponsors of approved testosterone products about class-wide labeling changes.
- The announcement was made via a press release (Exhibit 99.1).
Lipocine Inc. has updated its corporate presentation used for investor and analyst meetings. The filing serves as a formal notification of the update to ensure transparency in communications.
๐ Key Facts
- The company updated its corporate presentation (Exhibit 99.1).
- The update is intended for use with investors, analysts, and other stakeholders.
- Filed on February 11, 2025.
Lipocine Inc. issued an 8-K to announce the receipt of additional regulatory guidance regarding its product candidate LPCN 1154.
๐ Key Facts
- The company received new regulatory guidance for LPCN 1154 on February 6, 2025.
- The announcement was made via a press release incorporated by reference as Exhibit 99.1.
Lipocine Inc. has filed an 8-K to announce the update of its corporate presentation used for investor and analyst meetings.
๐ Key Facts
- The company updated its corporate presentation (Exhibit 99.1).
- The filing was made on January 13, 2025.
- The purpose is to provide current information to investors, analysts, and other stakeholders.
Lipocine Inc. announced that the FDA has granted Fast Track Designation to its drug candidate LPCN 1148 for the treatment of sarcopenia in patients with decompensated cirrhosis.
๐ Key Facts
- FDA granted Fast Track Designation to LPCN 1148 on December 17, 2024.
- Target indication: Sarcopenia in patients with decompensated cirrhosis.
- The announcement was made via a press release (Exhibit 99.1).
Lipocine Inc. has filed an 8-K to announce the update of its corporate presentation used for investor and analyst meetings.
๐ Key Facts
- The company updated its corporate presentation (Exhibit 99.1).
- The filing was made on December 13, 2024.
- The purpose is to provide current information to investors, analysts, and other stakeholders.
Lipocine Inc. issued an 8-K to announce the publication and discussion of its LPCN 1148 manuscript at The Liver Meeting (AASLD) 2024 Editorโs Cut Session held on November 16, 2024.
๐ Key Facts
- The company presented/discussed the LPCN 1148 Manuscript at the AASLD 2024 Editor's Cut Session.
- The event took place on November 16, 2024.
- The announcement was made via a press release filed as Exhibit 99.1.
Lipocine Inc. filed an 8-K to announce the issuance of a press release containing financial and operational results for the fiscal quarter ended September 30, 2024.
๐ Key Facts
- The filing is a standard announcement of quarterly earnings (Q3 2024).
- Report date: November 7, 2024.
- Period covered: Quarter ended September 30, 2024.
- Exhibit 99.1 contains the detailed financial and operational results.
Lipocine Inc. announced a poster presentation by Dr. Frank Greenway at the Obesity Societyโs Annual Obesity Week conference regarding clinical results for LPCN 2401.
๐ Key Facts
- Event Date: November 5, 2024
- Presentation Title: 'Oral LPCN 2401 Reduces Fat Mass and Increases Lean Mass in Men with Obesity'
- Presenter: Dr. Frank Greenway (Key Opinion Leader)
- Conference: Obesity Societyโs Annual Obesity Weekยฎ conference in San Antonio, Texas
Lipocine Inc. has entered into a Distribution and License Agreement with SPC Korea to commercialize its TLANDOยฎ product in South Korea for testosterone replacement therapy across multiple indications, including Klinefelter syndrome.
๐ Key Facts
- Agreement signed with SPC Korea ('SPC').
- Product: TLANDOยฎ (testosterone replacement therapy).
- Territory/Scope: Commercialization in South Korea for male deficiency/absence of endogenous testosterone and pediatric indications.
- Includes coverage for conditions associated with NDA No. 208088 and Klinefelter syndrome.
Lipocine Inc. has adopted a Third Amended and Restated Stockholder Rights Agreement to extend the expiration date of its existing shareholder rights plan until October 22, 2027. Additionally, the company filed an amendment to its Certificate of Designation for Series A Junior Participating Preferred Stock to account for the impact of a previous reverse stock split.
๐ฉ Red Flags
- The adoption of a shareholder rights plan (poison pill) can sometimes indicate management's defensive posture against potential takeover attempts or hostile bidders.
๐ Key Facts
- The Board adopted a Third Amended and Restated Stockholder Rights Agreement on October 22, 2024.
- The expiration date of the rights plan is extended from November 1, 2024, to October 22, 2027.
- The agreement aims to deter coercive takeover tactics and prevent an acquiror from gaining control without offering a fair price.
- Rights become exercisable if a person/group acquires 15% or more of common stock (the 'Acquiring Person').
- Filed a Certificate of Amendment to the Certificate of Designation of Series A Junior Participating Preferred Stock to reflect the May 11, 2023, reverse stock split.
Lipocine Inc. hosted a virtual Key Opinion Leader (KOL) event regarding its LPCN 2401 candidate for obesity management. The filing serves to announce the presentation of clinical/scientific data related to this pipeline asset.
๐ Key Facts
- Event Date: October 16, 2024
- Topic: Virtual KOL event on LPCN 2401 for improved body composition in obesity management
- The presentation is made available via the company's corporate website and filed as Exhibit 99.1.
Lipocine Inc. issued an 8-K to announce positive Phase 1 study results regarding oral brexanolone Quantitative EEG (qEGG). The filing serves as a vehicle to incorporate the company's press release into its official SEC record.
๐ Key Facts
- Announced positive oral brexanolone Quantitative EEG (qEGG) results from a Phase 1 study on October 10, 2024.
- The announcement is detailed in Exhibit 99.1.
- The filing was signed by Mahesh V. Patel, President and CEO.
Lipocine Inc. has entered into a Supply and Distribution Agreement with Pharmalink to commercialize its oral testosterone replacement therapy, TLANDOยฎ, in the Gulf Cooperation Council (GCC) region.
๐ Key Facts
- Agreement signed on October 8, 2024.
- Partner: Pharmalink.
- Product: TLANDOยฎ (oral testosterone replacement therapy).
- Territory: GCC countries including Saudi Arabia, Kuwait, UAE, Qatar, Bahrain, and Oman.
Lipocine Inc. filed an 8-K to disclose a presentation shared with investors during the H.C. Wainwright 8th Annual MASH Investor Conference on October 7, 2024.
๐ Key Facts
- The company presented at the H.C. Wainwright 8th Annual MASH Investor Conference on October 7, 2024.
- The presentation was shared virtually with investors.
- Exhibit 99.1 contains the full conference presentation.
Lipocine Inc. announced it will host a virtual Key Opinion Leader (KOL) event on October 16, 2024, regarding its LPCN 2401 candidate for obesity management.
๐ Key Facts
- Event Date: Wednesday, October 16, 2024, at 11:00 AM ET.
- Topic: Virtual KOL event on LPCN 2401 for improved body composition in obesity management.
- Format: Virtual presentation.
Lipocine Inc. announced its intention to present at the H.C. Wainwright 8th Annual MASH Investor Conference scheduled for October 7, 2024.
๐ Key Facts
- Company will participate in the H.C. Wainwright 8th Annual MASH Investor Conference.
- The conference is scheduled to take place virtually on October 7, 2024.
- The announcement was made via a press release filed as Exhibit 99.1.
Lipocine Inc. announced its intention to present Phase 2 data for LPCN 2401 at the Obesity Societyโs Annual ObesityWeekยฎ conference in November 2024.
๐ Key Facts
- The company will present Phase 2 data on LPCN 2401.
- Presentation scheduled for the ObesityWeekยฎ conference, held November 3 โ 6, 2024.
- Filing includes a press release (Exhibit 99.1) regarding the upcoming presentation.
Lipocine Inc. announced its intention to present at the H.C. Wainwright 26th Annual Global Investor Conference scheduled for September 9, 2024.
๐ Key Facts
- Event: Presentation at H.C. Wainwright 26th Annual Global Investor Conference
- Date of Event: September 9, 2024
- Filing Date: August 27, 2024
Lipocine Inc. filed an 8-K to announce the release of its financial and operational results for the second quarter ended June 30, 2024.
๐ Key Facts
- The filing is a standard announcement of quarterly earnings (Q2 2024).
- Report date: August 8, 2024.
- Financial results cover the period ending June 30, 2024.
This is an amendment to a previous 8-K filing regarding the results of Lipocine Inc.'s Annual Meeting held on June 5, 2024. The company is specifically disclosing the Board's decision following a non-binding stockholder vote on the frequency of advisory votes for executive compensation.
๐ Key Facts
- The amendment (8-K/A) was filed to supplement the original 8-K filed on June 5, 2024.
- Stockholders approved a non-binding resolution favoring an annual frequency for advisory votes on executive compensation.
- The Board of Directors has formally determined that advisory votes on executive compensation will continue to be held each year.
Lipocine Inc. announced positive topline results from a pivotal pharmacokinetic study for LPCN 1154 (oral brexanolone) for the treatment of postpartum depression. The study demonstrated bioequivalence to IV brexanolone, supporting the company's plan for an NDA submission by Q4 2024.
๐ฉ Red Flags
- None identified in this clinical update.
๐ Key Facts
- LPCN 1154 demonstrated bioequivalence to IV brexanolone across key PK parameters (Cmax, AUC 0-โ, and AUC 0-t) with 90% confidence intervals within the 80%-125% range.
- The study was a randomized, crossover trial in 23 participants (after excluding one outlier).
- LPCN 1154 was well tolerated; no severe or serious adverse events were reported.
- FDA has agreed to the company's proposal for a 505(b)(2) NDA filing based on this single pivotal PK bridging study.
- NDA submission is targeted for the end of Q4 2024.
Lipocine Inc. announced the presentation of 52-week Phase 2 study data for its drug candidate LPCN 1148 at the EASL Congress in Milan, Italy. The filing serves to incorporate clinical trial results into the public record via a press release and presentation.
๐ Key Facts
- Presented Phase 2 study data for LPCN 1148 on June 8, 2024.
- The study focuses on improving sarcopenia and hepatic encephalopathy (HE) in patients with cirrhosis.
- Data presented was from a 52-week randomized clinical trial.
- Presentation occurred during the late-breaking session at the European Association for Study of the Liver (EASL) Congress.
Lipocine Inc. held its annual general meeting of shareholders on June 5, 2024. The filing reports the results of shareholder votes regarding director elections, auditor ratification, executive compensation, and plan amendments.
๐ฉ Red Flags
- Significant 'Against' or 'Abstain' votes on the amendment to the 2014 Stock and Incentive Plan (543,323 against vs 740,829 for) suggests notable shareholder dissent regarding equity compensation structures.
๐ Key Facts
- Six directors were elected to one-year terms: Dr. Mahesh V. Patel, Jeffrey A. Fink, John W. Higuchi, Dr. Jill M. Jene, Dr. Richard Dana Ono, and Dr. Spyros Papapetropoulos.
- Shareholders ratified the appointment of Tanner LLC as independent registered public accountants for the fiscal year ending December 31, 2024.
- A non-binding advisory vote approved executive compensation packages.
- Shareholders approved an annual frequency (one year) for future advisory votes on executive compensation.
- The Fourth Amended and Restated 2014 Stock and Incentive Plan was approved by shareholders.
Lipocine Inc. announced the adoption of a cash bonus plan for employees and executives, alongside an amendment to its 2014 Stock and Incentive Plan to remove language regarding the repricing of underwater stock options.
๐ฉ Red Flags
- The removal of 'repricing of underwater stock options' language is a response to stockholder feedback, indicating past investor concerns regarding dilution or equity management.
๐ Key Facts
- On May 18, 2024, the Board adopted cash bonus targets for employees and named executive officers (NEOs).
- Target bonuses for NEOs range from 35% to 50% of their 2024 base salary.
- Bonus payouts are contingent on meeting 2024 corporate objectives: clinical milestones, commercial/business development milestones, and financial objectives.
- On June 3, 2024, the Board amended the proposed Fifth Amended and Restated 2014 Stock and Incentive Plan to remove language allowing for the repricing of underwater stock options without shareholder approval.
Lipocine Inc. filed an 8-K to announce the release of its financial and operational results for the first quarter ended March 31, 2024.
๐ Key Facts
- The filing is a standard announcement of quarterly earnings (Q1 2024).
- Results cover the period ending March 31, 2024.
- The primary content is contained in Exhibit 99.1 (Press Release).
Lipocine Inc. announced that it will deliver a late-breaking oral presentation of data from its Phase 2 study of LPCN 1148 at the upcoming European Association for Study of the Liver (EASL) Congress in June 2024.
๐ Key Facts
- The company is presenting Phase 2 study data for LPCN 1148.
- Presentation will be a 'late breaking oral presentation' at the EASL Congress.
- The event is scheduled for June 5-8, 2024.
Lipocine Inc. announced the completion of dosing in its pivotal registration study for LPCN 1154, a candidate targeting postpartum depression.
๐ Key Facts
- Completion of dosing phase for the pivotal registration study of LPCN 1154.
- LPCN 1154 is being developed to treat postpartum depression.
- The announcement was made via press release on May 1, 2024.
Lipocine Inc. has filed an 8-K to announce the update of its corporate presentation used for investor and analyst meetings.
๐ Key Facts
- The company updated its corporate presentation (Exhibit 99.1).
- The filing was made on April 29, 2024.
- The purpose is to provide updated information to investors, analysts, and other stakeholders.
Lipocine Inc. entered into a new At-The-Market (ATM) sales agreement with A.G.P./Alliance Global Partners to offer up to $10,616,169 in common stock. Simultaneously, the company terminated its existing ATM agreement with Cantor Fitzgerald & Co. to facilitate this transition.
๐ฉ Red Flags
- Potential for immediate equity dilution through the $10.6M ATM offering.
- Frequent switching of ATM agents can sometimes indicate a need for liquidity or dissatisfaction with previous terms/execution.
๐ Key Facts
- Entered into an ATM Agreement with A.G.P./Alliance Global Partners on April 26, 2024.
- The new offering capacity is up to $10,616,169 of common stock.
- A.G.P. will receive a 3.0% commission on aggregate gross proceeds from sales.
- Terminated the existing Controlled Equity Offering SM Sales Agreement with Cantor Fitzgerald & Co. effective immediately (waived notice period).
- The new agreement is pursuant to an existing Form S-3 Registration Statement.
Lipocine Inc. announced positive Phase 2 clinical trial results for its obesity management candidate, LPCN 2401. The company plans to present these findings via a webcast and conference call.
๐ Key Facts
- Announced positive Phase 2 clinical trial results for LPCN 2401 on April 11, 2024.
- LPCN 2401 is an oral proprietary combination of an anabolic androgen receptor agonist and ฮฑ-tocopherol (an antioxidant metabolic modifier).
- The study focused on obesity management and showed improved body composition in participants.
- Company scheduled a webcast/conference call to present the clinical results.
Lipocine Inc. announced positive topline results from its LPCN 1148 Phase 2 clinical study in patients with cirrhosis via a press release on March 28, 2024.
๐ Key Facts
- Announced positive topline results from the LPCN 1148 Phase 2 Study.
- The study focused on patients with cirrhosis.
- Results were communicated through a press release filed as Exhibit 99.1.
Lipocine Inc. announced the completion of subject enrollment and the dosing of the first cohort in its pivotal pharmacokinetic (PK) study for LPCN 1154, an oral brexanolone intended to treat Postpartum Depression (PPD). This study is a critical step toward filing a New Drug Application (NDA).
๐ Key Facts
- Enrollment for the LPCN 1154 pivotal pharmacokinetic (PK) study is complete.
- The first cohort of subjects has been dosed in the study.
- The PK study is designed to support a New Drug Application (NDA) for Postpartum Depression (PPD).
- The announcement was made via press release on March 25, 2024.
Lipocine Inc. has filed an 8-K to announce the update of its corporate presentation used for investor and analyst communications.
๐ Key Facts
- The company updated its corporate presentation (Exhibit 99.1).
- The filing was made on March 7, 2024.
- The purpose is to provide current information to investors, analysts, and other stakeholders.
Lipocine Inc. filed an 8-K to announce the release of its financial and operational results for the fiscal year ended December 31, 2023.
๐ Key Facts
- The filing was made on March 7, 2024.
- The report covers financial and operational results for the full year ending December 31, 2023.
- Results are provided via a press release attached as Exhibit 99.1.
Lipocine Inc. announced its intention to present at the 36th Annual Roth Conference on March 6, 2024.
๐ Key Facts
- Company will present at the 36th Annual Roth Conference.
- The announcement was made via a press release filed as Exhibit 99.1.
Lipocine Inc. issued an 8-K to announce a press release confirming the dosing regimen for its pivotal registration study of LPCN 1154, intended for treating postpartum depression.
๐ Key Facts
- The announcement pertains to the confirmation of a dosing regimen for the pivotal registration study of LPCN 1154.
- LPCN 1154 is targeting the treatment of postpartum depression.
- The event occurred on February 6, 2024, and was reported via 8-K on February 12, 2024.
Lipocine Inc. entered into a significant license agreement with Gordon Silver Limited (an affiliate of Verity Pharmaceuticals) to commercialize its TLANDO product and TLANDO XR in the US and Canada for testosterone replacement therapy.
๐ฉ Red Flags
- The agreement is subject to termination by either party in the event of material breach or bankruptcy of the licensee.
๐ Key Facts
- Agreement date: January 12, 2024.
- Total license fee: $11 million (initial payment of $2.5M received on signing).
- Payment schedule: $5M due Feb 1, 2024; $2.5M due by Jan 1, 2025; $1M due by Jan 1, 2026.
- Milestone payments: Up to $259 million in aggregate based on sales milestones.
- Royalties: Tiered rates between 12% and 16% of net sales in the US and Canada.
- Scope: Exclusive rights for TLANDO (testosterone replacement) and TLANDO XR in the US and Canada; Lipocine retains all other territories and non-field applications.
Lipocine Inc. filed an 8-K to announce its participation in the Biotech Showcase on January 8, 2024. The company also updated its corporate presentation for investor relations purposes.
๐ Key Facts
- The Company presented at the Biotech Showcase on January 8, 2024.
- An updated corporate presentation was released to be used with investors and analysts.
- The presentation is filed as Exhibit 99.1.